文献速递脑血管病外科神经重症

克拉生坦对日本动脉瘤性蛛网膜下腔出血患者脑血管痉挛相关并发症及全因死亡率的影响:两项随机3期试验

Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients.
PubMed 文献 · J Neurosurg · 2022-04-01

两项在日本57个中心开展的双盲、安慰剂对照3期研究,分别纳入动脉瘤经血管内栓塞或手术夹闭后固定的aSAH患者,随机给予静脉克拉生坦(10 mg/hr)或安慰剂,在aSAH后48小时内开始、持续至多15天。克拉生坦显著降低血管痉挛相关并发症与全因死亡率联合终点:栓塞组从28.8%降至13.6%(相对风险降低53%,95%CI 17%-73%),夹闭组从39.6%降至16.2%(相对风险降低59%,95%CI 33%-75%);汇总分析显示全因并发症/死亡及不良预后(二分法mRS)显著降低。

要点

  • 克拉生坦显著降低栓塞后血管痉挛相关并发症与全因死亡率(28.8%降至13.6%,RRR 53%,95%CI 17%-73%)。
  • 克拉生坦显著降低夹闭后血管痉挛相关并发症与全因死亡率(39.6%降至16.2%,RRR 59%,95%CI 33%-75%)。
  • 汇总分析显示全因并发症/死亡及不良预后(二分法mRS)显著降低,治疗中出现的不良事件与既往报告相似。

核心结论

  • 克拉生坦显著降低aSAH后血管痉挛相关并发症与全因死亡率的联合发生率,未发现非预期安全性问题。

研究设计与样本

  • 两项相似的双盲、安慰剂对照3期研究,在日本57个中心开展,患者为aSAH后动脉瘤已固定的患者,一项研究经血管内栓塞、另一项经手术夹闭。
  • 每项研究随机221例,全分析集220例(克拉生坦组各109例,安慰剂组各111例),按WFNS分级分层随机,1:1给予静脉克拉生坦(10 mg/hr)或安慰剂,aSAH后48小时内开始、至多15天。

主要发现

  • 栓塞后血管痉挛相关并发症与全因死亡率:克拉生坦组13.6% vs 安慰剂组28.8%,相对风险降低53%(95%CI 17%-73%)。
  • 夹闭后血管痉挛相关并发症与全因死亡率:克拉生坦组16.2% vs 安慰剂组39.6%,相对风险降低59%(95%CI 33%-75%)。
  • 预先计划的汇总分析显示全因并发症/死亡及不良预后(二分法mRS)显著降低,治疗中出现的不良事件与既往报告相似。

关键数值与推荐

  • 主要终点之一为aSAH后6周内血管痉挛相关并发症与全因死亡率(包括新发脑梗死、迟发性缺血性神经功能缺损及全因死亡)。
  • 第二主要终点为aSAH后6周内全因并发症(任何原因的新发脑梗死或迟发性缺血性神经功能缺损)与全因死亡率。
  • 还评估6周内主要并发症/死亡终点的各组分发生率及aSAH后12周患者结局(包括改良Rankin量表评分)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Clazosentan has been investigated globally for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). The authors evaluated its effects on vasospasm-related morbidity and all-cause mortality following aSAH in Japanese patients. METHODS: Two similar double-blind, placebo-controlled phase 3 studies were conducted in 57 Japanese centers in patients with aSAH, after aneurysms were secured by endovascular coiling in one study and surgical clipping in the other. In each study, patients were randomly administered intravenous clazosentan (10 mg/hr) or placebo (1:1) starting within 48 hours of aSAH and for up to 15 days after aSAH. Stratified randomization based on World Federation of Neurosurgical Societies grade was performed using a centralized interactive web response system. Vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH, including new cerebral infarcts and delayed ischemic neurological deficits as well as all-cause mortality, were the first primary endpoint in each study. The second primary endpoint was all-cause morbidity (new cerebral infarct or delayed ischemic neurological deficit from any causes) and all-cause mortality (all-cause morbidity/mortality) within 6 weeks post-aSAH. The incidence of individual components of the primary morbidity/mortality endpoints within 6 weeks and patient outcome at 12 weeks post-aSAH (including the modified Rankin Scale scores) were also evaluated. The above analyses were also performed in the population pooled from both studies. RESULTS: In each study, 221 patients were randomized and 220 were included in the full analysis set of the primary analysis (109 in each clazosentan group, 111 in each placebo group). Clazosentan significantly reduced the incidence of vasospasm-related morbidity and all-cause mortality after aneurysm coiling (from 28.8% to 13.6%; relative risk reduction 53%; 95% CI 17%-73%) and after clipping (from 39.6% to 16.2%; relative risk reduction 59%; 95% CI 33%-75%). All-cause morbidity/mortality and poor outcome (dichotomized modified Rankin Scale scores) were significantly reduced by clazosentan after preplanned study pooling. Treatment-emergent adverse events were similar to those reported previously. CONCLUSIONS: Clazosentan significantly reduced the combined incidence of vasospasm-related morbidity and all-cause mortality post-aSAH with no unexpected safety findings. Clinical trial registration nos.: JapicCTI-163368 and JapicCTI-163369 (https://www.clinicaltrials.jp).

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Endo H, Hagihara Y, Kimura N, et al. Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients. J Neurosurg. 2022. PMID: 35364589. doi:10.3171/2022.2.JNS212914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。